| Similar Articles |
|---|
 |
The Motley Fool
April 23, 2007
Brian Lawler |
Trimeris Isn't Tumbling Trimeris announces first-quarter sales numbers for its HIV drug Fuzeon. Shares of the company were up 25% last week after it reported stronger-than-expected sales of the fusion inhibitor.   |
The Motley Fool
January 30, 2008
Brian Lawler |
The Competition Bites Trimeris Rivals lead to lower sales of the small specialty pharmaceutical's only marketed drug. |
The Motley Fool
November 30, 2007
Brian Lawler |
Not What Trimeris Needs Small biopharma Trimeris revealed that it and partner Roche were being sued for patent infringement by Novartis over Trimeris' only marketed compound, Fuzeon. |
The Motley Fool
March 19, 2007
Brian Lawler |
Trimeris Gets Trimmed Shares of the drug developer are down after a management shakeup. With shares trading near their 52-week lows amid all the pessimism, now is a good time for less-risk adverse investors to buy in. |
The Motley Fool
April 23, 2004
Charly Travers |
A Difficult Drug Launch Investors expected a lot from Fuzeon, Trimeris' HIV drug therapy. However, anticipated sales for the biotechnology company didn't materialize. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
July 19, 2007
Brian Orelli |
Trimeris Reaches a Plateau Drug developer Trimeris needs to push another drug out of its pipeline because sales of its only drug, Fuzeon, appear to be hitting the wall. Investors, take note. |
The Motley Fool
April 24, 2007
Brian Lawler |
Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes. |
The Motley Fool
May 24, 2011
Brian Orelli |
J&J Approved, but Needs Help From a Friend The HIV combo product is the key. |
The Motley Fool
July 19, 2010
Brian Orelli |
Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so. |
The Motley Fool
May 2, 2007
Brian Lawler |
Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note. |
The Motley Fool
November 20, 2006
Karl Thiel |
Trimeris Begs for a Buyout The pharmaceutical's reorganization plan practically posts a "for sale" sign. So will Roche -- or someone else -- bite? Investors, take note. |
The Motley Fool
November 29, 2010
Brian Orelli |
Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily. |
The Motley Fool
July 13, 2004
Charly Travers |
With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market. |
The Motley Fool
August 15, 2007
Brian Lawler |
Call for Change at Trimeris A shareholder group criticizes tiny Trimeris about its spending on research. In an SEC filing, HealthCor, which owns 15% of the outstanding shares, called for the pharmaceutical company to cut back on its research and development expenses and to explore selling the company. |
The Motley Fool
October 16, 2007
Brian Orelli |
Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note. |
The Motley Fool
September 7, 2007
Brian Orelli |
Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells. |
The Motley Fool
June 26, 2008
Brian Lawler |
Ardea Takes the More Exciting Route Ardea Bioscicences announces phase 2a data for its lead anti-HIV drug that is good enough to encourage further testing. |
The Motley Fool
March 24, 2011
Brian Orelli |
It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors. |
Nursing
January 2011
Carl A. Kirton |
HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness. |
American Journal of Nursing
March 2010
David E. Vance |
Aging with HIV: Clinical Considerations for an Emerging Population Since the advent of highly active antiretroviral therapy, HIV infection has become a chronic, albeit life-threatening, condition that can be managed; therefore, more and more people are growing older with HIV. |
Chemistry World
April 20, 2009
Phil Taylor |
GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'. |
Chemistry World
July 11, 2012 |
Gsk Drug Shines in HIV Trial GlaxoSmithKline has announced good results for its HIV - Aids drug candidate dolutegravir, which has apparently outperformed Atripla tablets in Phase III. |
American Journal of Nursing
March 2010
Bradley-Springer et al. |
Every Nurse Is an HIV Nurse The evolution of HIV infection into a chronic disease has implications across all clinical care settings. Every nurse should be knowledgeable about the disease in order to provide high-quality care to people with or at risk for HIV. |
Managed Care
December 2007
Ed Silverman |
Drugs to Plan For in 2008 There are not many traditional medications in the pipeline, and those that are in development probably won't make waves. |
BusinessWeek
November 24, 2003
John Carey |
Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells. |
